Journal article

Early responsiveness of women with osteoporosis to teriparatide after therapy with alendronate or risedronate

Paul D Miller, Pierre D Delmas, Robert Lindsay, Nelson B Watts, Marjorie Luckey, Jonathan Adachi, Kenneth Saag, Susan L Greenspan, Ego Seeman, Steven Boonen, Suzanne Meeves, Thomas F Lang, John P Bilezikian

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM | ENDOCRINE SOC | Published : 2008

Abstract

BACKGROUND: Anabolic responsiveness to teriparatide can be blunted or delayed in patients previously treated with alendronate. The extent of this effect is different for other antiresorptives. This study evaluated the early anabolic effects of teriparatide in postmenopausal women with osteoporosis previously treated with alendronate or risedronate. METHODS: Patients treated for at least 24 months with alendronate or risedronate discontinued their bisphosphonate and received teriparatide for 12 months. The primary endpoint was a comparison of changes from baseline in N-terminal propeptide of type 1 collagen after 3 months between prior bisphosphonate groups. We also examined changes in other ..

View full abstract

University of Melbourne Researchers

Grants

Awarded by NATIONAL INSTITUTE ON AGING


Funding Acknowledgements

This work was supported by The Alliance for Better Bone Health (Procter & Gamble Pharmaceuticals and sanofi- aventis). The authors received editorial support in the preparation of this manuscript funded by The Alliance for Better Bone Health (Procter& Gamble Pharmaceuticals and sanofi- aventis). However, the authors were fully responsible for all content and editorial decisions, and received no financial support or other form of compensation related to the development of the paper.